It enrolled 751 adults with obesity and without type 2 diabetes and gave each the highest dose they tolerated of one drug for 72 weeks. Weight fell by 20.2% on tirzepatide and 13.7% on semaglutide. It was published in the New England Journal of Medicine in 2025.1
How the trial was run
SURMOUNT-5 was a phase 3b, open-label trial: participants knew which drug they were taking. They were assigned in equal numbers to tirzepatide, at 10 mg or 15 mg, or semaglutide, at 1.7 mg or 2.4 mg, depending on the highest dose each person tolerated, injected once a week.1 Those are the maintenance doses on the Zepbound and Wegovy labels, apart from Zepbound 5 mg and the newer Wegovy 7.2 mg.2,3
The main outcome was the percentage change in weight at week 72. The main secondary outcomes included reaching losses of at least 10%, 15%, 20% and 25%, and the change in waist size.1
What it found
- Weight fell by 20.2% on tirzepatide and 13.7% on semaglutide.
- Waist size fell by 18.4 cm against 13.0 cm.
- More people on tirzepatide reached each threshold of 10%, 15%, 20% and 25%.
- The most common side effects in both groups were in the stomach and gut, mostly mild to moderate and mainly during the dose climb.
Aronne et al., 2025.1
What it means
Before SURMOUNT-5, the two drugs could be compared only across separate trials: 20.9% on Zepbound 15 mg over 72 weeks in SURMOUNT-1 and 14.9% on Wegovy 2.4 mg over 68 weeks in STEP 1.4,5 SURMOUNT-5 put them in the same trial, with the same people and the same length, and the gap held: about 6.5 percentage points.
For a person weighing 110 kg, that difference is about 7 kg on average, a rough figure we calculated from the published percentages. Individual results vary widely on both drugs, so the averages describe groups rather than any one person. The report found tirzepatide ahead at every threshold it checked, from a 10% loss up to a 25% loss.
The trial also matters for people switching. Our page on switching from Wegovy to Zepbound explains what the labels say about moving from one to the other, and Ozempic and Zepbound sets out both direct trials, SURMOUNT-5 and SURPASS-2.
The earlier comparison in diabetes
SURPASS-2 had compared the two drugs in 1,879 adults with type 2 diabetes, but at diabetes doses: tirzepatide 5, 10 or 15 mg against semaglutide 1 mg, for 40 weeks. Weight fell by 1.9 to 5.5 kg more on tirzepatide, and HbA1c by 0.15 to 0.45 points more.6 SURMOUNT-5 answered the question for the weight-management doses, in people without diabetes, over a longer time. Both trials point the same way.
Cost
The price gap between the two brands also matters for many people. On November 20, 2026, our cost page lists Wegovy at $199 a month for the first two fills for new patients and $349 after that, and Zepbound from $299 a month, before insurance.7 Our page on GLP-1 costs without insurance keeps those prices current.
Limits
- Open-label. People knew which drug they took, which can affect behavior and reporting.
- Sponsor. It was funded by Eli Lilly, the maker of tirzepatide.
- Doses. It did not include Wegovy 7.2 mg, a higher dose that came later.
- Who took part. Only adults with obesity and without type 2 diabetes, so people with diabetes should look to SURPASS-2.
Aronne et al., 2025; WEGOVY label.1,3
Sources
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. Funded by Eli Lilly; NCT05822830. doi:10.1056/NEJMoa2416394
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2 and 14. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 2. accessdata.fda.gov
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
- Fr铆as JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021;385:503-515. doi:10.1056/NEJMoa2107519
- Dose Insider. GLP-1 cost without insurance: every self-pay price compared. Prices read November 20, 2026, from the makers' self-pay pages. doseinsider.com
Related analyses
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
Switching from Wegovy to Zepbound: the starting dose, the timing, and what the evidence covers
Wegovy vs Mounjaro: two drugs, two labels, and the trials that compared them
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Log your doses and weight and see how your own curve compares.
Open Dose Insider